Aeterna Zentaris Inc. has undergone a major transformation, rebranding itself as COSCIENS Biopharma Inc. This corporate transition reflects not only a nominal change but also a strategic overhaul aimed at better representing the company's diversified portfolio and innovative drive within the
Freudenberg Medical, known for its contributions to biopharmaceuticals and medical devices, continues to enhance its product offerings and global footprint. Highlighted in an August 2024 article by Feliza Mirasol, the company's business expansion strategy focuses on custom single-use
In a significant milestone for the biopharmaceutical industry, AGC Biologics' Seattle site successfully underwent a multi-product inspection by the U.S. Food and Drug Administration (FDA) in March 2024. This comprehensive evaluation was aimed at supporting Biologics License Applications (BLA)
Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,
The biopharmaceutical and life sciences industry is experiencing dynamic shifts, marked by strategic partnerships, innovative laboratory products, and enhanced service offerings. Companies are increasingly focusing on forming alliances, introducing state-of-the-art equipment, and improving their
Xeris Biopharma Holdings Inc. (NASDAQ: XERS) recently experienced a slight dip in its stock value, closing at $2.48, down -1.59% from the previous day. However, with positive analyst ratings, significant insider buying, and strong institutional support, there are several optimistic indicators for
